KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Assets (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Non-Current Assets data on record, last reported at $514.1 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 39.99% year-over-year to $514.1 million; the TTM value through Sep 2025 reached $1.7 billion, up 19.22%, while the annual FY2024 figure was $383.4 million, 10.1% up from the prior year.
  • Non-Current Assets reached $514.1 million in Q3 2025 per IONS's latest filing, up from $408.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $514.1 million in Q3 2025 and bottomed at $258.7 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $334.0 million, with a median of $348.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: plummeted 53.62% in 2021, then soared 39.99% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $266.6 million in 2021, then increased by 24.21% to $331.2 million in 2022, then increased by 5.14% to $348.2 million in 2023, then increased by 10.1% to $383.4 million in 2024, then soared by 34.09% to $514.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $514.1 million in Q3 2025, $408.0 million in Q2 2025, and $394.0 million in Q1 2025.